Children’s Cancer group. N Engl J Med 1999, 341:1165–1173.PubMedCrossRef 6. Pearson AD, Pinkerton CR, Lewis Selleckchem BYL719 IJ, Imeson J, Ellershaw C, Machin D, European Neuroblastoma Study Group, Children’s Cancer and selleck products Leukaemia
Group (CCLG formerly United Kingdom Children’s Cancer Study Group): High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 Neuroblastoma: a randomised trial. Lancet Oncol 2008, 9:247–256.PubMedCrossRef 7. Zage PE, Kletzel M, Murray K, Marcus R, Castleberry R, Zhang Y, London WB, Kretschmar C: Outcomes of the POG 9340/9341/9342 trials for children with high-risk Neuroblastoma: a report from the Children’s oncology group. Pediatr Blood Cancer 2008, 51:747–753.PubMedCrossRef 8. Lau L, Tai D, Weitzman S, Grant R, Baruchel S, Malkin D: Factors influencing survival
Acadesine molecular weight in children with recurrent neuroblastoma. J Pediatr Hematol Oncol 2004, 26:227–232.PubMedCrossRef 9. Laverdière C, Cheung NK, Kushner BH, Kramer K, Modak S, LaQuaglia MP, Wolden S, Ness KK, Gurney JG, Sklar CA: Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer 2005, 45:324–332.PubMedCrossRef 10. Clevers H: Wnt/beta-catenin signaling in development and disease. Cell 2006, 127:469–480.PubMedCrossRef 11. Logan CY, Nusse R: The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004, 20:781–810.PubMedCrossRef 12. MacDonald BT, Tamai K, He X: Wnt/beta-catenin signaling: Galeterone components, mechanisms, and diseases. Dev Cell 2009, 17:9–26.PubMedCentralPubMedCrossRef 13. Barker N, Clevers H: Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006, 5:997–1014.PubMedCrossRef 14. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, et al.: Tankyrase inhibition stabilizes axin and antagonizes Wnt sianaling. Nature 2009,
461:614–620.PubMedCrossRef 15. Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, Wei S, Hao W, Kilgore J, Williams NS, et al.: Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009, 5:100–107.PubMedCentralPubMedCrossRef 16. Xu D, Zheng C, Bergenbrant S, Holm G, Björkholm M, Yi Q, Gruber A: Telomerase activity in plasma cell dyscrasias. Br J Cancer 2001, 84:621–625.PubMedCentralPubMedCrossRef 17. MacNamara B, Wang W, Chen Z, Hou M, Mazur J, Gruber A, Porwit-MacDonald A: Telomerase activity in relation to pro- and anti-apoptotic protein expression in high grade non-Hodgkin’s lymphomas. Haematologica 2001, 86:386–393.PubMed 18.